Read the full article here.
SafeBridge Consultants has updated the status of its programme to assist pharmaceutical and biotechnology companies to identify contract manufacturing organisations that are qualified in the safe handling of potent active pharmaceutical ingredients (APIs) and drug products.
The SafeBridge potent compound safety certification programme provides drug innovators with an independent assessment of the manufacturing company’s capabilities to safely produce potent APIs and drug products. The programme also provides pharmaceutical manufacturers with a metric to evaluate their own performance and to encourage continuous improvement.
The SafeBridge certification applies to specific areas of facilities involved in potent compound work, and the evaluation considers performance in more than 60 programme elements.